Post conference news
Post conference news
We’d like to thanks you all so much for making the 2017 issue of the PAMM meeting a great success with outstanding science and great networking that generated discussions and collaborations.
We are delighted to share with you the latest news about the 38th EORTC-PAMM Winter Meeting held in Split.
70 delegates from 14 different countries attended the 2017 Meeting. 46 oral presentations were given during the 12 Plenary Sessions, over the 2,5 days of the conference. The 11 presented posters were highly appreciated by all delegates and the discussions were very fruitful during the breaks.
For the first time, we have introduced 2 Sessions entirely dedicated to the Biotech Labs on some of their ongoing novel targets and first-in-class drug development programs. The disease-oriented sessions were also highly appreciated giving together scientific and clinical insights on diseases such as pancreatic and colon cancers.
The Young Investigator Award has been handed out to the winners of the Best Poster and Best Presentation during the Awards Session on Saturday, March 18th.
You can download below the abstracts and oral presentations.
The outstanding venue, the fruitful networking, the high quality program, the social events, and last but not least great spring weather made the 2017 EORTC-PAMM Edition a remarkable success!
We will now be working and keep you posted on the 2018 PAMM meeting that will be organized by Prof. Giovanni Codacci-Pisanelli.
Looking forward meeting you in Rome next year.
G. J. Peters, Co-Chairman
• Welcome – E. RAYMOND, France
• Keynote Introduction Lecture: Evolution of Drug Development – E. CVITKOVIC, France
• MET as a Target for Liver and Head & Neck Cancer – S. FAIVRE, France
• Gene Screening for Target Therapy – C. LE TOURNEAU, France
• The microbiota as a Therapeutic Tool in Cancer Therapy – J. JIMENO, USA
• Targeting Stem Cells in Hepatocellular Carcinoma – S. BRUN, France (Not available)
• Vaccination Strategies for Pancreatic Adenocarcinoma – R. TROUVE, Switzerland
E. GIOVANNETTI, Netherlands
R. DANESI, Italy
• Use of small Molecule Kinase Inhibitors for Immuno-Oncology Applications: the Nanocyclix Approach – P. BLOM, France
• Immunotherapy and Immune-Monitoring – E. JORDANOVA, Netherlands
• Immunotherapy with and beyond Checkpoint Inhibitors – A. NAING, USA (Not available)
• Development of novel Proteasome Deubiquitinase Inhibitors – S. LINDER, Sweden (Not available)
• Characterization of Molecules derived from Marine Microorganisms, acting on Metastatic Breast Cancer Cells – A. DEZAIRE, France (Not available)
• Development of new Theranostic Alkoxyamines as Prodrugs against Glioblastoma – D. BURIC, France (Not available)
• New Ifosfamide Analogs for Immunotherapy and Nanomedecine against Cancer – J. DELAHOUSSE, France
• Influence of Genetic Polymorphisms on Cardiac Biomarker Concentrations under Doxorubicin Therapy – F. HELLMANN, Germany
• Modelling of Daunorubicin Release from Liposomes after Administration of DaunoXome® using a Population Pharmacokinetic Approach – M. LIEBICH, Germany
• Using RNA-sequencing to detect novel Splice Variants related to Drug Resistance in in vitro Cancer Models – R. SCIARRILLO, Netherlands
• TGF Beta Receptor Inhibitors from the Lab to the Clinic – K. BENHADJI, France
• Pharmacological Profile of PT-112, a Pyrophosphate Conjugate under Clinical Development in Advanced Solid Tumors – J. JIMENO, USA (Not available)
• Ex-vivo Evaluations of Novel Anticancer Agents using Fresh Tumor Explants and Biopsies – A. TIJERAS-RABALLAND, France
• First-in-Human Dose Studies with Immuno-Oncology Agents – M. LAHN, Switzerland (Not available)
• Relevance of miRNA as Targets & Biomarkers – P. GANDELLINI, Italy (Not available)
• The Science of Pharmacology in Early Drug Development – G.J. PETERS, Netherlands
• Molecular Pathology in Drug Development – J. CROS, France (Not available)
• Substrate-specific Effects of Pirinixic Acid Derivatives on ABCB1-Mediated Drug Transport – M. MICHAELIS, United Kingdom
• ABCB1 as predominant Resistance Mechanism in Cells with acquired SNS-032 Resistance – M. MICHAELIS, United Kingdom (Same as above)
• The Resistant Cancer Cell Line (RCCL) Collection: drug-adapted Cancer Cell lines as Preclinical Models of acquired Drug Resistance – M. MICHAELIS, United Kingdom (Same as above)
• miR-875-5p Reconstitution Radiosensitizes Prostate Cancer Cells and Xenografts through EGFR Suppression – R. EL BEZAWY, Italy
• The Challenge of Clonal Evolution upon Treatment for Precision Medicine – M. HEGI, Switzerland
• Nanomedicine in Oncology: Promise and Pitfalls – J. CICCOLINI, France
• Inhibitors of Tumor Microenvironment Signaling – E. RAYMOND, France
• Clinical/Translational Research in Jordan: The King Hussein Cancer Center Perspective, Success & Challenges – A. AL OMARI, Jordan
• Inhibition of Axl Receptor Tyrosine Kinase Abrogates the Cytoprotective Autophagic Flux in NSCLC Cells with Acquired Erlotinib Resistance and induces an Immunogenic Cell Death – A. ENGELSEN, Norway (Not available)
• NOTCH2 and PTP4A3 Gene Copy Number Alterations are associated with Prognosis and Support Novel Therapeutic Strategies for Malignant Pleural Mesothelioma – L. G. LEON, Italy (Not available)
• Optimization of the timing of Sequential Administration of Bevacizumab plus Cytotoxics in NSCLC by a Mathematical Model – S. BENZEKRY, France
• How do First-in-Human Clinical Trials look like in 2017? – G. HEMPEL, Germany
• Drugs Development Methodology: the unavoidable break with the past – A. AWADA, Belgium
• How relevant are Targets and Mechanisms of action for Drug Development? – J-P. BIZZARI, USA
• Innovations and Combinations for Novel Anticancer Strategies – A-R. HANAUSKE, Germany (Not available)
• Best Presentation: New Ifosfamide Analogs for Immunotherapy and Nanomedecine against Cancer – J. DELAHOUSSE, France
• Best Poster: Development of Inhibitors of αB-crystallin as potential Therapy against Triple Negative Breast Cancer – N. FOSU-MENSAH, United Kingdom